Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Biovail/Hoechst/Marion Merrell Dow

Executive Summary

Biovail/Hoechst/Marion Merrell Dow: Bioavail re-acquires license to its once-daily controlled-release diltiazem from Hoechst-Roussel, which licensed the product in 1993, Biovail says April 3. Hoechst is purchasing a controlling interest in Marion Merrell Dow, which filed a patent infringement suit regarding the diltiazem formulation in November 1993. MMD manufactures its own once-daily diltiazem, Cardizem CD. Biovail and Hoechst filed an antitrust suit against MMD Oct. 19, 1994. Within 30 days of the closing of the MMD deal, Hoechst will "withdraw or otherwise dismiss the patent-related complaint" filed by MMD "with prejudice"; Elan, which manufacturers Cardizem CD for MMD, also must drop its complaint. Hoechst has made a "financial proposal" to Biovail "relating to the withdrawal of the complaint"...

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts